A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective
Xiao Xu, Caroline Schaefer, Ágota Szende, Eduardo H. Genofre, Rohit Katial, Yen Chung
Abstract
This study was funded by AstraZeneca (Cambridge, UK). Drs Xu, Chung, Genofre, and Katial are or were AstraZeneca employees at the time this research was conducted and may be shareholders of AstraZeneca. Ms Schaefer and Dr Szende are employees of Labcorp Drug Development, which received funding from AstraZeneca to perform this research.
Topics & Concepts
MepolizumabMedicineBenralizumabDupilumabPopulationClinical trialAsthmaMarginal costIndirect costsCost effectivenessPharmacoeconomicsIntensive care medicineInternal medicineEnvironmental healthEosinophilRisk analysis (engineering)MicroeconomicsEconomicsAccountingBusinessAsthma and respiratory diseasesEosinophilic EsophagitisIL-33, ST2, and ILC Pathways